SEC Form 4	
------------	--

П

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OWR APPRO	VAL
OMB Number:	3235-0287
Estimated average burde	en
hours per response:	0.5

1. Name and Address of Reporting Person <sup>*</sup> PUCKETT DAN			2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>ShockWave Medical, Inc.</u> [ SWAV ]		5. Relationship of Reporting Person(s) to Issu (Check all applicable) Director 10% Ow				
P			—	_ x	Officer (give title below)	Other (specify below)			
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)		,	,			
C/O SHOCKWAVE MEDICAL, INC.			09/09/2019		Chief Financial Officer				
5403 BETSY	<b>ROSS DRIVE</b>								
			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv	vidual or Joint/Group Filir	ng (Check Applicable			
(Street)				Line)					
. ,		05054		X	Form filed by One Re	porting Person			
SANTA CLA		95054			Form filed by More that Person	an One Reporting			
(Citv)	(State)	(Zin)							

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
			Code V		Amount	(A) or (D) Price		Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock	09/09/2019		<b>M</b> <sup>(1)</sup>		62,974	A	\$2.196	70,974	D		
Common Stock	09/09/2019		М		8,538	A	\$3.416	79,512	D		
Common Stock	09/09/2019		М		3,488	A	\$4.026	83,000	D		
Common Stock	09/09/2019		S		30,467	D	\$34.3307(2)	52,533	D		
Common Stock	09/09/2019		S		43,433	D	<b>\$</b> 34.9369 <sup>(3)</sup>	9,100	D		
Common Stock	09/09/2019		S		1,100	D	\$35.9645(4)	8,000	D		

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of Deri Sec Acq (A) ( Disp of (I	umber vative urities uired or oosed o) (Instr. and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Employee Stock Option (Right to Buy)	\$2.196	09/09/2019		М			62,974	(5)	05/18/2026	Common Stock	62,974	\$0	84,566	D	
Employee Stock Option (Right to Buy)	\$3.416	09/09/2019		М			8,538	(6)	08/03/2027	Common Stock	8,538	\$0	7,855	D	
Employee Stock Option (Right to Buy)	\$4.026	09/09/2019		М			3,488	(7)	07/19/2028	Common Stock	3,488	\$0	8,807	D	

#### Explanation of Responses:

1. All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 8/8/2019.

The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from \$33.54 to \$34.53. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
 The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from \$34.54 to \$35.44. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
 The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from \$35.61 to \$36.00. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
 The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from \$35.61 to \$36.00. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
 Twenty-Five percent of the shares subject to the option vested on 4/15/17 and the balance of the shares shall vest in equal monthly installments thereafter for 36 months.

6. 1/48th of the shares subject to the option shall vest monthly from 7/21/17.

7. 1/48th of the shares subject to the option shall vest monthly from 7/19/18.

 
 /s/ Trinh Phung, as attorney-infact for Dan Puckett
 09/10/2019

 \*\* Signature of Reporting Person
 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.